ETX-155 is a Small Molecule owned by Eliem Therapeutics, and is involved in 4 clinical trials, of which 2 were completed, and 2 are planned.

ETX-155 acts by agonizing GABA A-type receptor. It is a neuroactive steroid that binds at the neurosteroid site on extrasynaptic and synaptic receptors. Binding at the extrasynaptic and synaptic receptors causes enhanced GABAergic tone and GABAergic synaptic transmission, leading to decreased neuron excitability and firing.

The revenue for ETX-155 is expected to reach a total of $3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the ETX-155 NPV Report.

ETX-155 is originated and owned by Eliem Therapeutics.

ETX-155 Overview

ETX-155 is under development for the treatment of major depressive disorder (MDD), perimenopausal depression and focal onset seizures (FOS). The drug candidate is administered through oral route. It is a next-generation, neuroactive steroid new chemical entity (NCE) that acts by targeting GABA A type receptor.

Eliem Therapeutics Overview

Eliem Therapeutics is a biotechnology company that develops and markets novel therapies for the treatment of chronic pain, psychiatry, epilepsy and other peripheral and central nervous system disorders. The company is headquartered in Redmond, Washington, the US.

The operating loss of the company was US$35.7 million in FY2021, compared to an operating loss of US$20.9 million in FY2020. The net loss of the company was US$47.5 million in FY2021, compared to a net loss of US$20.7 million in FY2020.

Quick View – ETX-155

Report Segments
  • Innovator
Drug Name
  • ETX-155
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.